Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults

Alimentary Pharmacology & Therapeutics
J LindsayG Chung-Faye

Abstract

Infliximab has been shown to be efficacious in moderate-to-severe Crohn's disease (CD). To evaluate the cost-effectiveness of scheduled maintenance treatment with infliximab in luminal and fistulizing CD patients. Markov models were constructed to simulate the progression of adult CD patients with and without fistulae during treatment with infliximab (5 mg/kg). Transitions were estimated from published clinical trials of infliximab. Standard care, comprising immunomodulators and/or corticosteroids was used as a comparator. An average weight of 60 kg was used to estimate the dose of infliximab. The costs and outcomes were discounted at 3.5% over 5 years. The primary effectiveness measurement was quality-adjusted life years (QALYs) estimated using EQ-5D. One-way and probabilistic sensitivity analyses were performed by varying the infliximab efficacy estimates, costs and utilities. The incremental cost per QALY gained was pound 26,128 in luminal CD and pound 29,752 in fistulizing CD at 5 years. Results were robust and remained in the range of pound 23,752- pound 38,848 for luminal CD and pound 27,047- pound 44,206 for fistulizing CD. Patient body weight was the most important factor affecting cost-effectiveness. Eight-week schedul...Continue Reading

References

Mar 8, 1980·Lancet·R F Harvey, J M Bradshaw
Jul 1, 1995·Scandinavian Journal of Gastroenterology·P MunkholmV Binder
Dec 1, 1993·Gastroenterology·P MunkholmV Binder
Nov 1, 1995·Gut·F MakowiecM Starlinger
Nov 21, 1997·Medical Care·P Dolan
Dec 17, 1997·Scandinavian Journal of Gastroenterology·P Blomqvist, A Ekbom
May 6, 1999·The New England Journal of Medicine·D H PresentS J van Deventer
May 29, 2001·Gastroenterology·K O ArseneauA F Connors
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Jul 20, 2002·Inflammatory Bowel Diseases·Jacques CosnesJean-Pierre Gendre
Aug 13, 2002·Journal of Clinical Gastroenterology·Joel H RubensteinRussell D Cohen
Oct 24, 2003·The American Journal of Gastroenterology·Brian G FeaganGary R Lichtenstein
Feb 6, 2004·Gastroenterology·Paul RutgeertsStephen B Hanauer
Feb 27, 2004·The New England Journal of Medicine·Bruce E SandsSander J van Deventer
Aug 13, 2004·Gut·M J CarterUNKNOWN IBD Section, British Society of Gastroenterology
Sep 28, 2004·International Journal of Technology Assessment in Health Care·Isabelle Jaisson-HotCyrille Colin
Sep 9, 2005·European Journal of Gastroenterology & Hepatology·Derek P JewellScot Buchan
Dec 27, 2005·Rheumatology·M SomervilleD G I Scott
Feb 17, 2006·Gut·S P L TravisUNKNOWN European Crohn's and Colitis Organisation
May 9, 2006·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Gary R LichtensteinWilliam J Sandborn
May 2, 2007·Annals of Internal Medicine·William J SandbornPaul F Pollack
Jul 20, 2007·The New England Journal of Medicine·Stefan SchreiberUNKNOWN PRECISE 2 Study Investigators
Sep 14, 2007·Alimentary Pharmacology & Therapeutics·C SaroB Otero
Sep 19, 2007·World Journal of Gastroenterology : WJG·Renato CavigliaMichele Cicala
Oct 16, 2007·Digestive Diseases and Sciences·Stephen J RudolphRobert P McCabe
Jan 1, 1997·Inflammatory Bowel Diseases·J C GregorB G Feagan

❮ Previous
Next ❯

Citations

Jan 14, 2012·Inflammatory Bowel Diseases·Daniel A SussmanMaria T Abreu
Mar 15, 2012·Inflammatory Bowel Diseases·Ashwin N AnanthakrishnanChin Hur
Sep 15, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Monia MarchettiGino R Corazza
Nov 2, 2011·Internal and Emergency Medicine·Antonio Di SabatinoGino R Corazza
Feb 6, 2010·Nature Reviews. Gastroenterology & Hepatology·Russell D Cohen
Jun 25, 2013·Inflammatory Bowel Diseases·Derek H TangEdward P Armstrong
Nov 21, 2013·SpringerPlus·Erkki J SoiniTaru Hallinen
Jan 29, 2011·PharmacoEconomics·Keith Bodger
Nov 27, 2008·World Journal of Gastroenterology : WJG·Selwyn Odes
Apr 10, 2010·World Journal of Gastroenterology : WJG·Jong Seung LeeYon Ho Choe
Sep 25, 2012·World Journal of Gastroenterology : WJG·Alan B R ThomsonHugh J Freeman
May 17, 2014·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·László GulácsiPetra Baji
Aug 21, 2013·Digestive Diseases and Sciences·Mike van der HaveMartijn G H van Oijen
Jul 14, 2009·Expert Opinion on Biological Therapy·Gerald W Dryden
Sep 17, 2015·Journal of Crohn's & Colitis·Dan GreenbergUNKNOWN Israeli IBD Research Nucleus [IIRN]
May 25, 2010·Alimentary Pharmacology & Therapeutics·D C MaloneM I Rahman
Nov 6, 2010·Alimentary Pharmacology & Therapeutics·M B SprakesP J Hamlin
Aug 13, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Taehwan ParkDong-Churl Suh
Nov 4, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Yogesh Suresh PunekarJames Lindsay
Feb 26, 2016·Inflammatory Bowel Diseases·Mark H FlasarRaymond Cross
Jan 1, 2013·Clinical Medicine Insights. Gastroenterology·Amosy E M'Koma
Jul 27, 2011·The American Journal of Gastroenterology·Ashwin N AnanthakrishnanJoshua R Korzenik
May 21, 2010·The American Journal of Gastroenterology·Geoffrey C NguyenSteven R Brant
Dec 31, 2010·Korean journal of pediatrics·Mi Jin Kim, Yon Ho Choe
Apr 11, 2017·Current Medicinal Chemistry·Laszlo GulacsiPeter L Lakatos
Sep 30, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Monia Marchetti, Nicola Lucio Liberato
Oct 21, 2019·Journal of Crohn's & Colitis·Nadia PillaiUNKNOWN Swiss IBD Cohort Study group
Apr 15, 2016·World Journal of Gastroenterology : WJG·Emily K WrightDanny Liew
May 19, 2019·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Fanni RenczPeter L Lakatos
Feb 1, 2020·Current Gastroenterology Reports·Jonathan A BeardBenjamin H Click
May 21, 2011·Journal of Medical Economics·Heidi WatersDamian H Augustyn
Apr 25, 2012·Pharmacotherapy·Derek H TangJeannie K Lee
Jul 17, 2018·Canadian Journal of Gastroenterology & Hepatology·Lachaine JeanOn Behalf Of The iGenoMed Consortium
Mar 25, 2019·Scandinavian Journal of Gastroenterology·Jung-Wook KimHyo Jong Kim
Aug 21, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Claire Smart, Christian P Selinger

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.